Lilly Feeds The Beast, But Is Novartis Animal Health Unit Worth The Price?
This article was originally published in The Pink Sheet Daily
Executive Summary
$5.4 billion deal boosts Lilly’s Elanco animal health business that adds both geographic scope and better product mix, but some investors snort at the high multiple.
You may also be interested in...
Emerging Markets Earnings Roundup: Eli Lilly (Part 6)
China and emerging markets are expected to come to the fore for Eli Lilly as it works through patent expirations in the United States, while Japan helped despite a weaker yen.
Investors Crow For Shares Of Zoetis As It Begins Trading On The NYSE
Zoetis makes its debut on the public stock exchange, garnering the highest priced IPO since Facebook began trading last year.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.